The Food and Drug Administration this week posted what critics call an "underwhelming" epilogue to the devastating outbreak of botulism in babies , which was linked to spore-contaminated formula made by ByHeart . Despite clear tracking of the contamination, the regulator still doesn't know how the bacteria arrived in the formula—or how to prevent it from happening again. "The FDA's investigation i...
The Food and Drug Administration this week posted what critics call an "underwhelming" epilogue to the devastating outbreak of botulism in babies , which was linked to spore-contaminated formula made by ByHeart . Despite clear tracking of the contamination, the regulator still doesn't know how the bacteria arrived in the formula—or how to prevent it from happening again. "The FDA's investigation into the root cause is ongoing with a focus on ingredients," the agency reported. In the void, three companies at the center of the investigation are left pointing fingers at each other, with none publicly taking responsibility for the contamination. Read full article Comments
Jeremy Siegel, Professor Emeritus of Finance at the Wharton School, discussed the recent market sell-off during a live financial news segment. The conversation focused on the sharp decline in the NASDAQ 100, which was described as an AI-led rout coinciding with climbing yields. He speaks with Romaine Bostick & Katie Greifeld on "The Close." (Source: Bloomberg)
Jeremy Siegel, Professor Emeritus of Finance at the Wharton School, discussed the recent market sell-off during a live financial news segment. The conversation focused on the sharp decline in the NASDAQ 100, which was described as an AI-led rout coinciding with climbing yields. He speaks with Romaine Bostick & Katie Greifeld on "The Close." (Source: Bloomberg)
A remarkable two-month sprint higher for major stock-market indexes encountered its first major hiccup on Friday as the Nasdaq Composite plummeted more than 1,121 points — the biggest one day point drop on record, according to Dow Jones Market Data.
A remarkable two-month sprint higher for major stock-market indexes encountered its first major hiccup on Friday as the Nasdaq Composite plummeted more than 1,121 points — the biggest one day point drop on record, according to Dow Jones Market Data.
A remarkable two-month sprint higher for major stock-market indexes encountered its first major hiccup on Friday as the Nasdaq Composite plummeted more than 1,121 points — the biggest one day point drop on record, according to Dow Jones Market Data.
A remarkable two-month sprint higher for major stock-market indexes encountered its first major hiccup on Friday as the Nasdaq Composite plummeted more than 1,121 points — the biggest one day point drop on record, according to Dow Jones Market Data.
In this article AZN-GB AZN Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:05 02:05 AstraZeneca CEO: AI helps us make smarter choices when developing drugs Mad Money with Jim Cramer AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout the research process. "The value of AI in our industry i...
In this article AZN-GB AZN Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:05 02:05 AstraZeneca CEO: AI helps us make smarter choices when developing drugs Mad Money with Jim Cramer AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout the research process. "The value of AI in our industry is productivity improvement," Soriot said on CNBC's " Mad Money " on Friday. "In the way you design a new medicine, a new drug, you can actually do it faster, do it smarter." The comments come as investors increasingly question whether the massive spending on artificial intelligence is producing meaningful returns in industries like healthcare. Soriot said AstraZeneca is already seeing practical applications across drug discovery and development, from identifying new targets to improving the design of potential medicines. "You can come up with new targets, but also you can optimize your molecule [and] remove what you think is going to be potential side effects from the molecule, and AI helps you do this," he said. Soriot noted that AI is also helping the company make better decisions about which drugs to advance through the development process. Through its partnership with Tempus AI, he said the company is using AI models to analyze data with the goal of improving drug discovery and increasing the odds of success in late-stage trials. "We have developed an agent that takes all this data together — clinical data, laboratory data — and helps us predict the probability of success of a Phase 3 trial," Soriot said. The potential payoff is significant. "We spend $300 million, $400 million, $500 million on a trial," Soriot said. "If you increase the probability of success, the productivity improvement is enormous." watch now VIDEO 9:12 09:12 AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer Mad Money with Jim Cramer Jim Cramer's Guide to Investing Click here to read Jim...
Waste Of The Day: Mismanagement At SF Zoo Authored by Jeremy Portnoy via RealClearInvestigations , Topline: The taxpayer-funded San Francisco Zoo "does not have a healthy or stable financial condition," according to a city audit released in May. The zoo has no written plans or budgets to guide its construction projects, and spent $12 million on them without city approva l. Employees are also alleg...
Waste Of The Day: Mismanagement At SF Zoo Authored by Jeremy Portnoy via RealClearInvestigations , Topline: The taxpayer-funded San Francisco Zoo "does not have a healthy or stable financial condition," according to a city audit released in May. The zoo has no written plans or budgets to guide its construction projects, and spent $12 million on them without city approva l. Employees are also allegedly hiring their friends and relatives as contractors. Key facts: The zoo is required to get approval from San Francisco's Recreation and Park Commission before paying more than $50,000 for a construction project. But employees never did so while spending millions on a new "Madagascar Center" and other huge projects, auditors found. There is also a "widespread view among staff that [the zoo] has a toxic workplace environment," according to the audit. Employees were allegedly chosen for senior roles based on "discrimination and favoritism," not "professional qualifications." The zoo spends more than $4 million on contracted services like security and advertising every year, but there is no evidence that any of them went through a competitive bidding process to find the best price. The zoo keeps no records of its contractors and was unable to tell auditors how much they are being paid, the audit found. The audit also confirmed that former zoo CEO Tanya Peterson's fiancé was hired to perform concerts, and other relatives of zoo staff received more than $800,000 for construction projects . The San Francisco Chronicle first exposed the nepotism allegations in 2024, which eventually contributed to Peterson's resignation. The City of San Francisco gives the zoo $4 million in funding every year, though that amount has not increased since 1993. Most of the zoo's revenue comes from tickets, but low attendance has caused the zoo to outspend its budget for at least the last eight years. The zoo hid this fact from the city by projecting "unrealistically high" attendance numbers each ye...
Gene Sperling, President of Sperling Economic Strategies and former director of the National Economic Council, discussed the recent U.S. jobs report, highlighting that the headline numbers were stronger than expected and suggest a low likelihood of recession despite ongoing geopolitical and economic challenges. He noted that while job creation appears broad-based, some gains—such as the 70,000 hos...
Gene Sperling, President of Sperling Economic Strategies and former director of the National Economic Council, discussed the recent U.S. jobs report, highlighting that the headline numbers were stronger than expected and suggest a low likelihood of recession despite ongoing geopolitical and economic challenges. He noted that while job creation appears broad-based, some gains—such as the 70,000 hospitality jobs—may be influenced by seasonal factors like World Cup-related hiring. He speaks with Romaine Bostick and Katie Greifeld on "The Close." (Source: Bloomberg)
Meta's Mark Zuckerberg wanted to build a massive data center. And Louisiana leaders wanted Meta to choose their state as its home. But making that happen took a lot of negotiation — and secrecy. Bloomberg reporter Riley Griffin takes host Sarah Holder inside the deal. (Source: Bloomberg)
Meta's Mark Zuckerberg wanted to build a massive data center. And Louisiana leaders wanted Meta to choose their state as its home. But making that happen took a lot of negotiation — and secrecy. Bloomberg reporter Riley Griffin takes host Sarah Holder inside the deal. (Source: Bloomberg)
PM Images/DigitalVision via Getty Images Introduction The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts. However, since this list is only produced once per month, the data in it can quickly get out of date. Furthermore, with around 700 companies on the list, the sheer amount of data can quickly become overwhelming. In ...
PM Images/DigitalVision via Getty Images Introduction The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts. However, since this list is only produced once per month, the data in it can quickly get out of date. Furthermore, with around 700 companies on the list, the sheer amount of data can quickly become overwhelming. In this weekly series, I highlight recent and upcoming dividend related activity for dividend stocks on the Dividend Champions list. In the data presented below, Yield is forward annualized and Years reflects the up-to-date streak, including dividends declared since the last edition of the Dividend Champions list. Dividend Changes In the past week, the following companies declared dividends which changed from their previous payouts. Increases: Company Symbol Ex-Div Pay Old Rate New Rate Increase Yield Years Essential Properties Realty Trust, Inc. ( EPRT ) 6/30 7/14 0.31 0.32 3.23% 4.23% 9 Greif, Inc. ( GEF ) 6/17 7/1 0.56 0.62 10.71% 3.90% 6 Medtronic plc ( MDT ) 6/26 7/17 0.71 0.72 1.41% 3.53% 49 Oil-Dri Corporation of America ( ODC ) 8/7 8/21 0.205 0.225 9.76% 1.07% 24 UnitedHealth Group Incorporated ( UNH ) 6/15 6/23 2.21 2.32 4.98% 2.32% 17 W. R. Berkley Corporation ( WRB ) 6/23 7/2 0.09 0.1 11.11% 0.58% 25 Click to enlarge Decreases: None Last Chance to Buy These dividend growth stocks have ex-dividend dates approaching. The following tables indicate the last day you can buy these stocks in order to be eligible for the upcoming dividend. Tables are sorted alphabetically by symbol. Monday Jun 8 (Ex Div 6/9) Company Symbol Pay Date Payout Price Yield Years Ameren Corporation ( AEE ) 6/30 0.75 109.27 2.75% 13 Becton, Dickinson and Company ( BDX ) 6/30 1.05 151.16 2.78% 54 CME Group Inc. ( CME ) 6/25 1.3 257.40 2.02% 16 Canadian National Railway Company ( CNI ) 6/30 0.915 CAD 120.38 2.19% 31 The St. Joe Company ( JOE ) 6/25 0.16 64.87 0.99% 6 Public Service Enterprise Group I...